Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 8870901 | https://doi.org/10.1155/2021/8870901

Bin Ye, Liqun Lai, "Yu Shi An Chang Fang Ameliorates TNBS-Induced Colitis in Mice by Reducing Inflammatory Response and Protecting the Intestinal Mucosal Barrier", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 8870901, 9 pages, 2021. https://doi.org/10.1155/2021/8870901

Yu Shi An Chang Fang Ameliorates TNBS-Induced Colitis in Mice by Reducing Inflammatory Response and Protecting the Intestinal Mucosal Barrier

Academic Editor: Yoshiki Mukudai
Received28 Sep 2020
Revised17 Mar 2021
Accepted24 Apr 2021
Published04 May 2021

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease that is related to the occurrence of colon cancer. This study aimed to investigate the underlying mechanism by which Yu Shi An Chang Fang (YST) treated UC. 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) was used to construct the UC model. The body weight, fecal viscosity, and fecal bleeding of all mice were recorded every day to calculate the DAI value. The pathological changes in colon tissues were observed by hematoxylin-eosin (H&E) staining. The levels of tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and myeloperoxidase (MPO) reflecting inflammation and the levels of malondialdehyde (MDA), glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) reflecting oxidative stress in colon tissues were all measured by their assay kits. The mRNA expression of TNF-α, IL-1β, and IL-6 in colon tissues was detected by quantitative reverse transcription-PCR (qRT-PCR). The expression of proteins related to pyroptosis and the colonic mucosal barrier was analyzed by Western blot. As a result, TNBS caused decreases in body weight and colon lengths, triggered serious histological damage, promoted inflammation, oxidative stress, and pyroptosis, and destroyed the colonic mucosal barrier. The above changes caused by TNBS in colitis mice could be partially reversed by YST. In conclusion, YST ameliorates TNBS-induced UC in mice by reducing the inflammatory response and protecting the intestinal mucosal barrier.

1. Introduction

Ulcerative colitis (UC), also known as chronic nonspecific ulcerative colitis, is characterized by inflammation and ulcerative lesions in the rectal (sigmoid) colonic mucosa and submucosa, and the entire colon and terminal ileum can be destroyed in severe cases [1]. UC is difficult to cure and has a high recurrence rate, which is associated with the occurrence of colon cancer [2]. Listed as one of the troublesome diseases by the World Health Organization, this disease has been widely valued by the medical community. According to a report, the incidence of UC in North America and Europe is as high as 23.14/100,000 and 57.9/100,000, respectively [3]. The latest epidemiological data show that the prevalence and incidence of UC in the Chinese mainland are on the rise sharply, with incidence 1.33/100,000 at present [4].

Important pathogenesis of UC is the imbalance of proinflammatory cytokines and anti-inflammatory cytokines, which means the content of serum anti-inflammatory factors in the UC active period is lower than that in the remission period, while the content of proinflammatory factors is higher than that in the remission period [5]. Moreover, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) in UC patients are higher than those in the control group. There are significant differences in serum levels of TNF-α, IL-6, and IL-8 in patients with UC at different stages [6]. Cytokine imbalance in the human body immediately leads to the activation of various inflammatory cells to release a variety of inflammatory factors, which ultimately induces a chronic inflammatory response in the intestinal tissues. In addition, the colonic mucosal barrier plays an important role in the pathogenesis of UC [7, 8]. A recent study has shown that intestinal epithelial cells are a highly dynamic tissue that can respond to signals transmitted by microbiota and immune system, thereby regulating barrier function. Meanwhile, abnormal signal transduction between epithelial cells and neighboring immune cells may promote immune dysregulation of UC [9]. The colonic mucosal barrier includes epithelial cells and the intercellular tight junction (TJ) [10, 11]. The disruption of TJ can destroy the paracellular barrier, thus leading to the enhancement in mucosal permeability and drastic mucosal inflammation in UC [12, 13].

Yu Shi An Chang Fang (YST) is a typical Chinese medicine prescription for treating UC rats through alleviating the occurrence of mucosal hyperplasia and ulcer and improves the level of inflammatory factors such as TNF-α, IL-8, and IL-10 in serum and intestinal mucosa [14]. The main ingredients of YST are Scutellaria baicalensis 20 g, Astragalus 15 g, Atractylodes 10 g, Licorice 10 g, Radix Paeoniae Alba 20 g, Cinnamon 5 g, Pueraria 15 g, Carbonized Catnip 15 g, Radix Sanguisorbae 30 g, Bletilla Striata 10 g, Frankincense 5 g, Herba Patriniae 30 g, Sargent Gloryvine 15 g, and Panax Notoginseng powder 3 g. However, there is a lack of research related to the underlying mechanism by which YST treats UC.

Therefore, the purpose of this study was to investigate the mechanism by which YST alleviates 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) induced UC in mice.

2. Materials and Methods

2.1. Colitis Mice and YST Treatment

The program was approved by the Animal Experimental Ethics Review Committee of Hangzhou TCM Hospital. Twenty male BALB/c mice (8 weeks, 17–20 g) were purchased from the Animal Experimental Center of Zhejiang Province. All mice were randomly divided into four groups, named as the control group (Control, 0.9% saline), colitis group (Model, 100 mg/kg TNBS), low-YST dose group (YST-L, 1 mL/kg YST), and high-YST dose group (YST-H, 10 mL/kg YST). To induce colitis, 5 mg of TNBS was dissolved in 0.2 ml of 50% ethanol. Each group consisted of five mice.

Each group except the control group was modeled. After anesthesia, mice were given 100 mg/kg TNBS every day by rectal perfusion. After seven days, mice in YST-L group and YST-H group were, respectively, given 1 mL/kg YST and 10 mL/kg YST by gavage every day, lasting 7 days. A total of 3 mL of YST solution and normal saline was given by gavage each time. The control group and the model group were given 3 mL normal saline by gavage. At the end of the experiment, all mice were fasted for 24 h and euthanized. There was no death of mice during the model construction. Colon lengths were recorded and colon specimens were divided into two sections. One section was frozen in liquid nitrogen for further analysis, and the other was immediately fixed in 4% paraformaldehyde solution, prepared by conventional methods after 48 h. After hematoxylin-eosin (H&E) staining, pathological changes of the colon were observed under an inverted microscope.

2.2. Disease Activity Index (DAI)

At the beginning of the experiment, the DAI of all the mice was evaluated daily. DAI was a comprehensive score of weight loss, fecal viscosity, and fecal bleeding [15]. DAI = (weight loss score + stool character score + stool blood condition score)/3.

2.3. Enzyme-Linked Immunosorbent Assay (ELISA)

Colon tissues from all mice were homogenized with lysis buffer and centrifuged at 1000 r/min at 4°C for 15 min to obtain the supernatant. The levels of tumor necrosis factor-α (TNF-α) (cat. no. PT512), interleukin-1 beta (IL-1β) (cat. no. PI301), and interleukin-6 (IL-6) (cat. no. PI326) in the colon supernatant were determined by ELISA kits (Beyotime) according to the manufacturer’s protocol.

2.4. Quantitative Reverse Transcription-PCR (qRT-PCR)

The colon tissues were fully ground to powder in liquid nitrogen. After grinding, Trizol reagent was added to EP tube, which was then centrifuged to obtain the total RNAs. The cDNAs of TNF-α, IL-1β, and IL-6 were synthesized using the Transcriptor First Strand cDNA Synthesis Kit and qPCR analysis conducted by Power SYBR Green. The thermocycling conditions were as follows: initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 15 s, annealing at 60˚C for 30 s, and extension at 72°C for 25 s. The primer sequences were as follows: TNF-α forward, 5′-CAA AGT AGA CCT GCC CAG AC-3′; reverse, 5′-GAC CTC TCT CTA ATC AGC CC-3′; IL-1β forward, 5′-AAA AGC TTG GTG ATG TCT GG-3′; reverse, 5′-TTT CAA CAC GCA GGA CAG G-3′; IL-6 forward, 5′-GTG TGA AAG CAG CAA AGA GGC-3′; reverse, 5′-CTG GAG GTA CTC TAG GTA TAC-3′; GAPDH forward, 5′-CATGAGAAGTATGACAACAGCCT-3′ and reverse, 5′-AGTCCTTCCACGATACCAAAGT-3′. The mRNA expression of TNF-α, IL-1β, and IL-6 was calculated by the 2−△△CT method with the internal reference as GAPDH.

2.5. Western Blot Analysis

After extraction of proteins from colon tissues, the determination of protein concentration was dependent on the BCA Protein Assay kit. 30 µg sample per lane was uploaded and separated through 12% SDS-PAGE gradient gel. The proteins were transferred to the PVDF membrane, which was sealed with 5% nonfat milk at 4°C for 2 h and added with primary antibodies including pyrin domain containing 3 (NLRP3) (ab263899, Abcam), anti-ASC (cat. no. AG-25B-0006, Adiogen), anti-pro caspase-1 (ab52079, Abcam), anti-Cleaved caspase-1 (#89332, Cell signaling pathway), anti-ZO1 (ab276131, Abcam), anti-Occludin (OCLN) (ab216327, Abcam), and anti-Claudin 1 (CLDN1) (ab180158, Abcam) at 4°C overnight. The next day, the membrane was incubated with the appropriate antihorseradish peroxidase-conjugated antibody and visualized through enhanced chemiluminescence detection. The gray value of the target protein expression was calculated by Image-Pro Plus software.

2.6. Measurement of Myeloperoxidase (MPO) Activity and Oxidative Stress Level

MPO activity was used to reflect whether neutrophil infiltration into inflamed colonic mucosa happened. The MPO activity (ab155458, Abcam) was measured by the O-dianisidine method, and levels of malondialdehyde (MDA) (cat. no. S0131S, Beyotime), glutathione peroxidase (GSH-Px) (cat. no. S0056, Beyotime), and superoxide dismutase (SOD) (cat.no. S0103, Beyotime) were quantified by their assay kits in the supernatant of colonic tissues.

2.7. Statistical Analysis

All the data presented as mean ± standard deviation were analyzed with the SPSS 22.0. One-way analysis of variance (ANOVA) was used to compare the significance of the differences in multiple groups, followed by Tukey’s test. was considered a significant difference among groups.

3. Results

3.1. Effects of YST on Clinical Manifestations of TNBS-Induced Colitis Mice

The body weights of mice in the Model group were obviously decreased and YST from low dose to high dose gradually improved the body weights of mice (Figure 1(a)). No significant difference was found in DAI values in the Model group, YST-L group, and YST-H group in the first 7 days, and YST from low dose to high dose downregulated the DAI value, especially from day 11 to day 14 (Figure 1(b)).

3.2. Effects of YST on Colon Tissues of TNBS-Induced Colitis Mice

The colon length of mice in the Model group became shorter, which was increasingly improved by YST from low dose to high dose. Of note, the colon length of mice in the YST-H group was longer than that in the YST-L group (Figure 2(a)). TNBS induction resulted in colonic mucosa injury and inflammatory cell infiltration that were significantly ameliorated by YST therapy (Figure 2(b)).

3.3. YST Alleviates Inflammation and Oxidative Stress in TNBS-Induced Colitis Mice

Inflammation and oxidative stress are classic features of colitis, and thus the inflammatory cytokines and factors related to oxidative stress were detected herein for the verification of the role of YST in the TNBS-induced colitis mice model. The levels of TNF-α, IL-1β, and IL-6 in colon tissues of colitis mice were elevated by contrast with those in the Model group. YST from low dose to high dose gradually decreased the levels of TNF-α, IL-1β, and IL-6 in colon tissues of colitis mice (Figure 3(a)). The changes in mRNA expression of TNF-α, IL-1β, and IL-6 in these four groups were similar to those in levels of TNF-α, IL-1β, and IL-6 (Figure 3(b)). As shown in Figure 3(c), MPO activity was enhanced in colon tissues of colitis mice, while YST suppressed the MPO activity (Figure 3(c)). MDA expression was decreased and the expression of GSH-Px and SOD was increased in colon tissues of colitis mice, which was reversed by YST treatment (Figure 3(d)).

3.4. YST Improves TNBS-Induced Colitis by Inhibiting Pyroptosis

The expression of pyroptosis related proteins (NLRP3, ASC, and Cleaved caspase-1) was upregulated in colon tissues of colitis mice and YST downregulated the above protein expression (Figure 4).

3.5. YST Improves TNBS-Induced Colitis by Protecting Integrity of the Colonic Mucosal Barrier

Structural impairment of the colonic mucus barrier is a critical factor for the pathogenesis of colitis at the early stage [16]. The decreased expression of tight junction proteins (ZO-1, OCLN, and CLDN1) in colon tissues of colitis mice challenged by TNBS was enhanced by YST treatment, indicating the defective colonic mucosal barrier could be restored by YST (Figure 5).

4. Discussion

TNBS can destroy the integrity of the colonic mucosal barrier, increase epithelial permeability, and induce strong inflammatory reaction, which enables the use of TNBS to be a typical method to construct the UC animal model [17, 18]. In this study, TNBS induction caused decreases in body weights and colon lengths and serious histological damage in colitis mice, which was similar to the results presented in previous studies [19, 20].

Although western medicine can instantly relieve symptoms of patients in previous treatments, the relapse of disease and the toxic and side effects of repeated drugs after treatment, all affect the treatment effect, safety, physical tolerance, and cooperation duration of UC patients. Thanks to minor side effects, Chinese medicine possessing anti-inflammatory effects has been increasingly investigated in recent decades [2124]. The main ingredients of YST are Scutellaria baicalensis 20 g, Astragalus 15 g, Atractylodes 10 g, Licorice 10 g, Radix Paeoniae Alba 20 g, Cinnamon 5 g, Pueraria 15 g, Carbonized Catnip 15 g, Radix Sanguisorbae 30 g, Bletilla Striata 10 g, Frankincense 5 g, Herba Patriniae 30 g, Sargent Gloryvine 15 g, Panax Notoginseng powder 3 g. Scutellaria baicalensis Georgi ,and Paeonia lactiflora Pall could treat UC [25, 26]. Cinnamaldehyde (CA) is a main active ingredient of cinnamon and CA could alleviate dextran sulfate sodium (DSS)-induced colitis by inhibiting activation of NLRP3 inflammasome [27]. One herb of Qingre Zaoshi Liangxue Fang (QRZSLXF) was Bletilla Striata and QRZSLXF could also treat UC by regulating the DOR-β-arrestin1-Bcl-2 signal transduction pathway [28]. Inflammation and oxidative stress in various diseases could be alleviated by the ingredients in YST, such as Scutellaria baicalensis [29], Astragalus [30], Atractylodes [31], Licorice [32], Penta-O-galloyl-β-d-glucose (obtained from Radix Paeoniae Alba) [33], Cinnamon [34], Mangiferin (obtained from Pueraria) [35], Bletilla Striata [36], and Casperome (extracted from Frankincense) [37]. In this study, we found that YST effectively suppressed TNBS-induced colonic inflammation showed by reversing changes in body weight, DAI, colonic length, and histological damage in the Model group. Moreover, the colonic levels of MPO and levels of TNF-α, IL-1β, IL-6, and MDA were decreased, and the levels of GSH-Px and SOD were increased in the YST-treated mice, thus demonstrating the anti-inflammatory and antioxidative stress properties of YST.

The integrity of the intestinal barrier depends on the robust innate immune responses, epithelial paracellular permeability, epithelial cell integrity, and the production of mucus [38]. Chitosan could protect against UC in mice by promoting dominant intestinal microflora and regulating the expressions of TNF-α, CLDN1, OCLN, and ZO-1 [39]. Artesunate could feasibly relieve people from UC by increasing the expression of intestinal mucosal barrier-related proteins and inhibiting inflammatory response [40]. Huang-lian-Jie-du Decoction (HLJDD) could suppress the NF-κB signaling pathway and enhance intestinal barrier function to treat DSS-induced UC mice [41]. In addition, swelling, plasma membrane lysis, chromatin fragmentation, and the release of proinflammatory substances of cells, which are presentations of pyroptosis, are closely related to the occurrence and development of UC [4244]. Curcumin could significantly inhibit the activation of NLRP3 inflammasome in DSS-induced mice, reduce the expression of IL-1, IL-6, and other inflammatory cytokines, and alleviate the symptoms of colitis in DSS-induced mice [45]. The therapeutic effect of Baicalin on DSS-induced UC mice was positively correlated with its dosage, and Baicalin inhibited the activation of nuclear transcription factor-κB (NF-κB) and NLRP3 inflammasome, and at the same time reduced the levels of TNF-α and IL-1 in serum and colon tissues [46]. Therefore, we speculated that the effect of YST might partially suppress the pyroptosis and enhance the intestinal mucosa tight junctions as the colonic mucosal barrier. In this study, the expression of NLRP3, ASC, and Cleaved caspase-1 was increased while the expression of CLDN1, OCLN, and ZO-1 was decreased in colon tissues of colitis mice, which were reversed by YST to near normal levels.

In conclusion, YST ameliorates TNBS-induced UC in mice by reducing inflammatory response and pyroptosis and improves the intestinal barrier function, uncovering the underlying mechanism of the protective effect of YST on UC.

Data Availability

Data will be available upon request to the corresponding author.

Conflicts of Interest

The authors declare they have no conflicts of interest.

References

  1. R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-Biroulet, and J.-F. Colombel, “Ulcerative colitis,” The Lancet, vol. 389, no. 10080, pp. 1756–1770, 2017. View at: Publisher Site | Google Scholar
  2. C. Polytarchou, D. W. Hommes, T. Palumbo et al., “MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice,” Gastroenterology, vol. 149, no. 4, pp. 981–992, 2015. View at: Publisher Site | Google Scholar
  3. S. C. Ng, H. Y. Shi, N. Hamidi et al., “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies,” Lancet (London, England), vol. 390, no. 10114, pp. 2769–2778, 2018. View at: Publisher Site | Google Scholar
  4. G. Cui and A. Yuan, “A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease,” Frontiers in Medicine (Lausanne), vol. 5, p. 183, 2018. View at: Publisher Site | Google Scholar
  5. L. Hualong, Z. Jiajia, W. Xianrong, and D. O. Gastroenterology, “Cytokines reflects severity of active ulcerative colitis,” Chinese Journal of Clinicians (Electronic Edition), vol. 9, no. 6, pp. 929–931, 2015. View at: Google Scholar
  6. R. Yi, J. Chang, X. Liu, and N. Hao, “Expressions and significance of TNF-α, IL-6 and IL-8 in patients with ulcerative colitis at different degrees,” Progress in Modern Biomedicine, vol. 15, no. 14, pp. 2641–2644, 2015. View at: Google Scholar
  7. L. Poritz, L. Harris, A. Kelly, and W. Koltun, “Increase in the tight junction protein claudin-1 in intestinal inflammation,” Digestive Diseases and Sciences, vol. 56, pp. 2802–2809, 2011. View at: Publisher Site | Google Scholar
  8. A. R. Janecke, P. Heinz-Erian, and T. Müller, “Mechanisms underlying dysregulation of electrolyte absorption in inflammatory bowel disease-associated diarrhea,” Inflammatory Bowel Diseases, vol. 22, no. 6, pp. E17–E18, 2016. View at: Publisher Site | Google Scholar
  9. I. B. Jeffery, P. W. O'Toole, L. Öhman et al., “An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota,” Gut Microbiota, vol. 61, no. 7, pp. 997–1006, 2012. View at: Publisher Site | Google Scholar
  10. T. Y. Ma, G. K. Iwamoto, N. T. Hoa et al., “TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 286, no. 3, pp. G367–G376, 2004. View at: Publisher Site | Google Scholar
  11. C. M. Niessen, “Tight junctions/adherens junctions: basic structure and function,” Journal of Investigative Dermatology, vol. 127, no. 11, pp. 2525–2532, 2007. View at: Publisher Site | Google Scholar
  12. M. C. Arrieta, K. Madsen, J. Doyle, and J. Meddings, “Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse,” Gut Microbiota, vol. 58, no. 1, pp. 41–48, 2008. View at: Publisher Site | Google Scholar
  13. K. L. Edelblum and J. R. Turner, “The tight junction in inflammatory disease: communication breakdown,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 715–720, 2009. View at: Publisher Site | Google Scholar
  14. L. Lai and B. Ye, “Research of the effect of Yu’s enema on IL-8, IL-10, TNF-α levels to ulcerative colitis rats,” Chinese Journal of Health Laboratory Technology, vol. 26, no. 22, pp. 3221–3223, 2016. View at: Google Scholar
  15. L. Chao, Z. Li, J. Zhou et al., “Shen-Ling-Bai-Zhu-San improves dextran sodium sulfate-induced colitis by inhibiting caspase-1/caspase-11-mediated pyroptosis,” Frontiers in Pharmacology, vol. 11, p. 814, 2020. View at: Publisher Site | Google Scholar
  16. S. Van der Post, K. S. Jabbar, G. Birchenough et al., “Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis,” Gut Microbiota, vol. 68, no. 12, pp. 2142–2151, 2019. View at: Publisher Site | Google Scholar
  17. S. S. Sadar, N. S. Vyawahare, and S. L. Bodhankar, “Ferulic acid ameliorates TNBS-induced ulcerative colitis through modulation of cytokines, oxidative stress, iNOs, COX-2, and apoptosis in laboratory rats,” EXCLI Journal, vol. 15, pp. 482–499, 2016. View at: Publisher Site | Google Scholar
  18. Z. Gao, C. Yu, H. Liang et al., “Andrographolide derivative CX-10 ameliorates dextran sulphate sodium-induced ulcerative colitis in mice: involvement of NF-κB and MAPK signalling pathways,” International Immunopharmacology, vol. 57, pp. 82–90, 2018. View at: Publisher Site | Google Scholar
  19. P. Gu, L. Zhu, Y. Liu, L. Zhang, J. Liu, and H. Shen, “Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF-kappaB pathway and apoptosis in mice,” International Immunopharmacology, vol. 50, pp. 152–160, 2017. View at: Publisher Site | Google Scholar
  20. L. Zhu, P. Gu, and H. Shen, “Gallic acid improved inflammation via NF-κB pathway in TNBS-induced ulcerative colitis,” International Immunopharmacology, vol. 67, pp. 129–137, 2019. View at: Publisher Site | Google Scholar
  21. M. Wu, A. Shen, Y. Chen et al., “Xinhuang tablets improve intestinal barrier function via regulating epithelial tight junctions in dextran sulfate sodium-induced ulcerative colitis mice,” Journal of Medicinal Food, vol. 24, no. 1, pp. 33–39, 2021. View at: Publisher Site | Google Scholar
  22. X. Ke, F. Zhou, Y. Gao et al., “Qing Hua Chang Yin exerts therapeutic effects against ulcerative colitis through the inhibition of the TLR4/NF-κB pathway,” International Journal of Molecular Medicine, vol. 32, no. 4, pp. 926–930, 2013. View at: Publisher Site | Google Scholar
  23. L. Shi, J. Wang, Q. Yang et al., “Effect of Yang-activating and stasis-eliminating decoction from traditional Chinese medicine on intestinal mucosal permeability in rats with ulcerative colitis induced by dextran sulfate sodium,” Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan, vol. 37, no. 4, pp. 452–460, 2017. View at: Google Scholar
  24. X. Wang, D. Li, Y. Zhang, S. Wu, and F. Tang, “Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway,” Experimental and Therapeutic Medicine, vol. 15, no. 5, pp. 4477–4484, 2018. View at: Publisher Site | Google Scholar
  25. P. Chen, X. Zhou, L. Zhang et al., “Anti-inflammatory effects of Huangqin tang extract in mice on ulcerative colitis,” Journal of Ethnopharmacology, vol. 162, pp. 207–214, 2015. View at: Publisher Site | Google Scholar
  26. S. Liang, X. Deng, L. Lei et al., “The comparative study of the therapeutic effects and mechanism of baicalin, baicalein, and their combination on ulcerative colitis rat,” Frontiers in Pharmacology, vol. 10, p. 1466, 2019. View at: Publisher Site | Google Scholar
  27. S. Qu, Y. Shen, M. Wang, X. Wang, and Y. Yang, “Suppression of miR-21 and miR-155 of macrophage by cinnamaldehyde ameliorates ulcerative colitis,” International Immunopharmacology, vol. 67, pp. 22–34, 2019. View at: Publisher Site | Google Scholar
  28. H. Fan, X.-X. Liu, L.-J. Zhang et al., “Intervention effects of QRZSLXF, a Chinese medicinal herb recipe, on the DOR-β-arrestin1-Bcl2 signal transduction pathway in a rat model of ulcerative colitis,” Journal of Ethnopharmacology, vol. 154, no. 1, pp. 88–97, 2014. View at: Publisher Site | Google Scholar
  29. J.-J. Chen, C.-C. Huang, H.-Y. Chang et al., “Scutellaria baicalensis ameliorates acute lung injury by suppressing inflammation in vitro and in vivo,” The American Journal of Chinese Medicine, vol. 45, no. 1, pp. 137–157, 2017. View at: Publisher Site | Google Scholar
  30. S. Adesso, R. Russo, A. Quaroni, G. Autore, and S. Marzocco, “Astragalus membranaceus extract attenuates inflammation and oxidative stress in intestinal epithelial cells via NF-κB activation and Nrf2 response,” International Journal of Molecular Sciences, vol. 19, no. 3, p. 800, 2018. View at: Publisher Site | Google Scholar
  31. Y. Xie, X. Zhan, J. Tu et al., “Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways,” Journal of Ethnopharmacology, vol. 272, Article ID 113925, 2021. View at: Publisher Site | Google Scholar
  32. Q. Man, Y. Deng, P. Li et al., “Licorice ameliorates cisplatin-induced hepatotoxicity through antiapoptosis, antioxidative stress, anti-inflammation, and acceleration of metabolism,” Frontiers in Pharmacology, vol. 11, Article ID 563750, 2020. View at: Publisher Site | Google Scholar
  33. J. Peng, K. Li, W. Zhu, R. Nie, R. Wang, and C. Li, “Penta-O-galloyl-β-d-glucose, a hydrolysable tannin from Radix Paeoniae Alba, inhibits adipogenesis and TNF-α-mediated inflammation in 3T3-L1 cells,” Chemico-Biological Interactions, vol. 302, pp. 156–163, 2019. View at: Publisher Site | Google Scholar
  34. F. Haidari, M. Mohammadshahi, B. Abiri, M. Zarei, and M. Fathi, “Cinnamon extract supplementation improves inflammation and oxidative stress induced by acrylamide: an experimental animal study,” Avicenna Journal of Phytomedicine, vol. 10, no. 3, pp. 243–252, 2020. View at: Google Scholar
  35. R. K. Bulugonda, K. A. Kumar, D. Gangappa et al., “Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome,” Scientific Reports, vol. 7, p. 42683, 2017. View at: Publisher Site | Google Scholar
  36. F. Jiang, M. Li, H. Wang et al., “Coelonin, an anti-inflammation active component of bletilla striata and its potential mechanism,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4422, 2019. View at: Publisher Site | Google Scholar
  37. K. Loeser, S. Seemann, S. König et al., “Protective effect of casperome (®), an orally bioavailable frankincense extract, on lipopolysaccharide- induced systemic inflammation in mice,” Frontiers in Pharmacology, vol. 9, p. 387, 2018. View at: Publisher Site | Google Scholar
  38. L. Pastorelli, C. De Salvo, J. Mercado, M. Vecchi, and T. Pizarro, “Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics,” Frontiers in Immunology, vol. 4, p. 280, 2013. View at: Publisher Site | Google Scholar
  39. J. Wang, C. Zhang, C. Guo, and X. Li, “Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora,” International Journal of Molecular Sciences, vol. 20, no. 22, p. 5751, 2019. View at: Publisher Site | Google Scholar
  40. S. Yin, H. Yang, Y. Tao et al., “Artesunate ameliorates DSS-induced ulcerative colitis by protecting intestinal barrier and inhibiting inflammatory response,” Inflammation, vol. 43, no. 2, pp. 765–776, 2020. View at: Publisher Site | Google Scholar
  41. Z. Yuan, L. Yang, X. Zhang, P. Ji, Y. Hua, and Y. Wei, “Huang-lian-jie-du decoction ameliorates acute ulcerative colitis in mice via regulating NF-κB and Nrf2 signaling pathways and enhancing intestinal barrier function,” Frontiers in Pharmacology, vol. 10, p. 1354, 2019. View at: Publisher Site | Google Scholar
  42. L. Vande Walle and M. Lamkanfi, “Pyroptosis,” Current Biology: CB, vol. 26, no. 13, pp. 568–572, 2016. View at: Publisher Site | Google Scholar
  43. Y.-Y. Yuan, K.-X. Xie, S.-L. Wang, and L.-W. Yuan, “Inflammatory caspase-related pyroptosis: mechanism, regulation and therapeutic potential for inflammatory bowel disease,” Gastroenterology Report, vol. 6, no. 3, pp. 167–176, 2018. View at: Publisher Site | Google Scholar
  44. E. M. Davis, Y. Kaufmann, H. Goyne et al., “Pyroptosis of intestinal epithelial cells is crucial to the development of mucosal barrier dysfunction and intestinal inflammation,” Gastroenterology, vol. 152, no. 5, p. S967, 2017. View at: Publisher Site | Google Scholar
  45. Z. Gong, S. Zhao, J. Zhou et al., “Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1β production,” Molecular Immunology, vol. 104, pp. 11–19, 2018. View at: Publisher Site | Google Scholar
  46. Y. Sun, Y. Zhao, J. Yao et al., “Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation,” Biochemical Pharmacology, vol. 94, no. 2, pp. 142–154, 2015. View at: Publisher Site | Google Scholar

Copyright © 2021 Bin Ye and Liqun Lai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views228
Downloads310
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.